Cesium carbonate → Benzothiazepine analog 11

HRID 1485768Notes

Reaction equation

HRID 1485768 reaction equation
[C:1]([N:4]1[C:13]2[C:8](=[CH:9][C:10](Br)=[CH:11][CH:12]=2)[N:7]([C:15]([O:17][CH:18]2[CH2:21][CH2:20][CH2:19]2)=[O:16])[CH2:6][C@@H:5]1[CH3:22])(=[O:3])[CH3:2].CC1(C)C(C)(C)OB([C:31]2[CH:32]=[N:33][N:34]([CH:36]3[CH2:41][CH2:40][S:39](=[O:43])(=[O:42])[CH2:38][CH2:37]3)[CH:35]=2)O1.C(=O)([O-])[O-].[Cs+].[Cs+].O1CCOCC1>CC(OC1C=CC=C(OC(C)C)C=1C1C(P(C2CCCCC2)C2CCCCC2)=CC=CC=1)C.CC(OC)(C)C.C1C=[C-]C(CCN)=CC=1.Cl[Pd+].O>[C:1]([N:4]1[C:13]2[C:8](=[CH:9][C:10]([C:31]3[CH:32]=[N:33][N:34]([CH:36]4[CH2:41][CH2:40][S:39](=[O:42])(=[O:43])[CH2:38][CH2:37]4)[CH:35]=3)=[CH:11][CH:12]=2)[N:7]([C:15]([O:17][CH:18]2[CH2:21][CH2:20][CH2:19]2)=[O:16])[CH2:6][C@@H:5]1[CH3:22])(=[O:3])[CH3:2]

Participants

7

Reactant 4

HCID 10796Cesium carbonateHCID 312751,4-DioxaneHCID 118080227(S)-cyclobutyl 4-acetyl-7-bromo-3-methyl-3,4-dihydroquinoxaline-1(2H)-carboxylateHCID 1239933294-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)-1lambda6-thiane-1,1-dione

Product 1

HCID 118080527Benzothiazepine analog 11Yield 47%

Reagents, catalysts & solvents 2

HCID 66572931HCID 66572931, compoundCatalystHCID 962WaterSolvent

Conditions

Temperature
80 °C

Procedure

A mixture of (S)-cyclobutyl 4-acetyl-7-bromo-3-methyl-3,4-dihydroquinoxaline-1(2H)-carboxylate (0.098 g, 0.267 mmol), 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)tetrahydro-2H-thiopyran 1,1-dioxide (0.097 g, 0.296 mmol), XPhos Precatalyst 2nd Generation (0.021 g, 0.027 mmol), cesium carbonate (0.261 g, 0.801 mmol), 1,4-dioxane (1.2 mL) and water (0.2 mL) was heated at 80° C. overnight. The reaction mixture was cooled to room temperature, filtered through a pad of Celite, and concentrated. The residue was purified via column chromatography on silica gel (Biotage 25 g column, gradient elution with 10-100% ethyl acetate-hexane). The resulting off-white solid was further purified via column chromatography on silica gel (Biotage 25 g column, gradient elution with 2-5% methanol-dichloromethane) to afford cyclobutyl (3S)-4-acetyl-7-[1-(1,1-dioxo-1λ6-thian-4-yl)-1H-pyrazol-4-yl]-3-methyl-1,2,3,4-tetrahydroquinoxaline-1-carboxylate (60 mg, 47%) as a white solid. 1H NMR (300 MHz, CDCl3) δ ppm 1.07 (d, J=7.04 Hz, 3 H), 1.61-1.74 (m, 1 H), 1.76-1.91 (m, 1 H), 2.05-2.19 (m, 2 H), 2.21 (s, 3 H), 2.34-2.48 (m, 2 H), 2.52-2.76 (m, 4 H), 3.12 (ddd, J=13.63, 8.79, 4.25 Hz, 2 H), 3.41-3.57 (m, 3 H), 4.07 (dd, J=12.61, 6.45 Hz, 1 H), 4.48 (tt, J=7.66, 3.92 Hz, 1 H), 5.05 (quin, J=7.55 Hz, 1 H), 5.17 (br s, 1 H), 7.09-7.23 (m, 2 H), 7.68 (s, 1 H), 7.77 (s, 1 H), 8.08 (s, 1 H). MS (ESI, pos. ion) m/z 487 [M+H]+.

Workup

  1. temperatureThe reaction mixture was cooled to room temperature
  2. filtrationfiltered through a pad of Celite
  3. concentrationconcentrated
  4. customThe residue was purified via column chromatography on silica gel (Biotage 25 g column, gradient elution with 10-100% ethyl acetate-hexane)
  5. customThe resulting off-white solid was further purified via column chromatography on silica gel (Biotage 25 g column, gradient elution with 2-5% methanol-dichloromethane)

Sources & evidence

ORD record
ord-ee564a5d933a4f1d920ac1be418fdba5
Source dataset
uspto-grants-2016_08
Patent number
US09422281B2

Reaction notes

Loading…